COMMUNIQUÉS West-GlobeNewswire

Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis
25/02/2019
MIST-2 study meets primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, good tolerability in confirmatory MIST-2 Study NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc [...]
Establishment Labs to Announce Fourth Quarter and Full Year 2018 Financial Results
25/02/2019
NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics [...]
Assure Holdings Receives DTC Eligibility and Approval for Uplisting to OTCQB
25/02/2019
DENVER, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “ Company ” or “ Assure ”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, has received approval from the Depository [...]
Hemostemix Announces UC Davis Health Added as a Trial Site for Phase II Clinical Trial
25/02/2019
CALGARY, Alberta, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from UC Davis Health (“UC [...]
Advantis Corp Announces Imminent Lease Signing for OC Location, a Tripling of Monthly Amster-Can Orders with Existing Client
25/02/2019
NEWPORT BEACH, CA, Feb. 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – ADVANTIS CORPORATION (OTC PINK: ADVT) CEO, Darren Cherry, announced that he plans on signing the lease agreement for the Orange County packaging [...]
Chembio Diagnostics to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019
25/02/2019
MEDFORD, N.Y., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial [...]
Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding
25/02/2019
– Amendment to Deerfield Facility Agreement Becomes Effective – – John H. Johnson Appointed Permanent Chief Executive Officer – – Company to Report Fourth Quarter and Full Year 2018 Financial Results on March 13, 2019 [...]
Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer
25/02/2019
- Former Head of U.S. Cardiovascular Medical Affairs at Amgen and Global Cardiovascular Medical Affairs at AstraZeneca to lead clinical development of MAT9001, a potential best-in-class prescription-only omega-3 drug [...]
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
25/02/2019
-First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- -First patient enrolled in a Phase 1/2 clinical trial of CTX001 for patients with sickle cell disease- -On track to [...]
Rockland Immunochemicals and Cellaria Sign Worldwide Distribution Agreement
25/02/2019
Partnership targets broader availability of new models and tools for cancer research CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Cellaria, LLC , a scientific innovator that develops revolutionary new models for [...]
Misonix to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27
25/02/2019
FARMINGDALE, N.Y., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, [...]
BioCorRx Appoints Two Finance Veterans to the Board of Directors
25/02/2019
ANAHEIM, CA, Feb. 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today the [...]
Hoth Therapeutics Inc. Announces the Addition of Dr. Adam Friedman, M.D. to the Company's Scientific Advisory Board
25/02/2019
NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Hoth Therapeutics, Inc.(NASDAQ:HOTH), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as [...]
Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Accepted as Oral Presentation at the 2019 Transplantation & Cellular Therapy (TCT) Annual Meeting
25/02/2019
First ever demonstration that the spectrum of toxicities seen in CAR-T clinical trials can be effectively prevented in vivo Enhanced anti-tumor activity, improved overall survival, and improved durability of response [...]
TYME Receives FDA Guidance on Pivotal Trial for SM-88 in Treatment for Advanced Pancreatic Cancer
25/02/2019
NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced that it received design guidance for a [...]
Galectin Therapeutics to Present at Berenberg NASH Day in New York
25/02/2019
NORCROSS, Ga., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin, the Company’s [...]
VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results
25/02/2019
Top-line data from Hepatitis B (Sci-B-Vac®) Phase 3 PROTECT trial expected mid-year 2019 Encouraging early immunogenicity data from GBM Phase 1/2a supports advancing into Part B of the study License and Collaboration [...]
Progressive Care Inc. Garners Coverage in CBS Miami for Creating Custom-Made Lotion Alternatives to Opioids
25/02/2019
MIAMI, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Progressive Care Inc. ( OTCQB: RXMD ), a personalized healthcare services and technology company, today announced that it has garnered media coverage in CBS Miami for creating [...]
Eidos Therapeutics to Host Conference Call and Webcast to Discuss ATTR-CM Phase 3 Trial (ATTRibute-CM) Design
25/02/2019
SAN FRANCISCO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need caused by transthyretin [...]

Pages